Institut Pasteur

Centre National De La Recherche Scientifique

Institut Curie

Sylvie Pochet

Philippe Marliere

Wilhelm Tischer

Muriel Gelin

Gilles Labesse

Hans-Georg Ihlenfeldt

Octavian Barzu

Hiroshi Sakamoto

Liliane Assairi

Olivier Dussurget

Guillaume Poncet-Montange

Madeleine Bouzon

Elisabeth Pistotnik

Philippe Marlière

The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim 1. The compounds are useful in the prevention and/or treatment of bacterial infections. 

Antibacterial compounds

The invention relates to a method for artificial in vivo evolution of proteins, said method making it possible to bring about the evolution of a protein X by complementation of a relative protein Y, X and Y both belonging to the same class of enzyme commission (EC) nomenclature or belonging to related classes. The mutants D133E and R104Q of desoxycytidine kinase (DCK) were obtained; both of said mutations result in acquisition of thymidine kinase activity by DCK.

Mutants of deoxycytidine kinase having extended enzymatic activity

The invention concerns novel nucleotide analogues comprising a reactive hydrazide function used as initial synthons for preparing compounds (formula I) capable of inducing mutations or capable of inhibiting a DNA polymerase or a kinase. The invention also concerns nucleic acids comprising said nucleotide and nucleoside analogues. Among such compounds, can be cited in particular the compound of formula (I) 

Combinatorial production of nucleotide and nucleoside (XiTP) analogues

The present invention relates to a method for the in vitro enzymatic synthesis of deoxyribonucleosides and enzymes suitable for this method.

Enzymatic synthesis of deoxyribonucleosides

Growing community of inventors

Paris, France

Sylvie Pochet